Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Endometrial Cancer
100%
Dinaciclib
100%
Endometrial Cancer Cell Line
60%
Cell Cycle Progression
40%
Cyclin-dependent Kinase Inhibitor
40%
DNA Repair
20%
Therapeutic Potential
20%
Novel Therapies
20%
Bcl-2 Expression
20%
5-year Survival
20%
Phosphorylation
20%
Cancer Therapy
20%
Cisplatin
20%
Cellular Processes
20%
Improved Patient Outcomes
20%
Success Rate
20%
RNA-dependent RNA Polymerase (RdRP)
20%
Carboxy Terminal Domain
20%
Female Cancer
20%
Tumor Cancer
20%
Primary Cells
20%
Multiple Keys
20%
Type II Endometrial Cancer
20%
Stud
20%
Medicine and Dentistry
Uterine Cancer
100%
Dinaciclib
100%
Endometrial Cancer Cell Line
60%
Cancer
40%
Cell Cycle Progression
40%
Cyclin Dependent Kinase Inhibitor
40%
Malignant Neoplasm
20%
Cisplatin
20%
Survival Rate
20%
Carboxy Terminal Sequence
20%
Cancer Treatment
20%
DNA Repair
20%
Tumor
20%
RNA Polymerase
20%
Biochemistry, Genetics and Molecular Biology
Cancer Cell
100%
Cyclin-Dependent Kinase
66%
Cell Cycle Progression
66%
Transcription
33%
C-Terminus
33%
Bcl-2
33%
DNA Repair
33%
Survival Rate
33%
Cisplatin
33%
RNA Polymerase
33%
Primary Cell
33%
Neuroscience
Cell Line
100%
Cell Cycle Progression
66%
Cyclin-Dependent Kinase
66%
DNA Repair
33%
C-Terminus
33%
Cisplatin
33%
Bcl-2
33%
RNA Polymerase
33%
Pharmacology, Toxicology and Pharmaceutical Science
Endometrium Cancer
100%
Dinaciclib
100%
Cyclin Dependent Kinase Inhibitor
28%
Malignant Neoplasm
14%
Survival Rate
14%
Cisplatin
14%
RNA Polymerase
14%
Cellular Processes
14%